HOT TOPIC Discussion: New Evidence Supporting COVID-19 Convalescent Plasma as An Effective Alternative Treatment Option with Immunosuppressed Patients (22EL-748) – Free for everyone!

Please note: AABB reserves the right to make updates to this program.

Live Program Date: Thursday, June 30, 2022 - On-Demand Available

Program Number: 22EL-748


This on-demand hot topic discussion is complimentary to all but registration is required. After signing up on GoToWebinar the video will immediately begin to play.

Faculty responses to your questions during the live program can be found on the GoToWebinar platform or you can view them here.

  • Program Description

    Approximately seven million (or 2.7%) US adults are immunocompromised and are therefore more likely to experience severe and prolonged illness from COVID-19 infection, with limited treatment options. Evidence suggests that treatment with high-titer CCP may provide an effective therapeutic alternative in this patient population when other options have proven to be ineffective. Join experts as they discuss the data around the use of high-titer CCP collected from donors with recent breakthrough COVID-19 infections. Which patients can most benefit from this therapy and how? How effective is the treatment with CCP as compared to other therapies? A discussion will also address the FDA permitted use and current guidance. An extended question and answer period will follow brief presentations.

    Learning Objectives

    After participating in this educational activity, participants should be able to:

    • Describe the new information establishing the efficacy of CCP in immunosuppressed patients.
    • Review regulatory status of CCP and its use, as authorized by FDA.
    • Assess the advantages of CCP treatment in relation to other antiviral therapies for use with immunosuppressed patients.


    Moderator: Nigel Paneth, MD, MPH, University Distinguished Professor, Emeritus, Departments of Epidemiology & Biostatistics and Pediatrics & Human Development, College of Human Medicine, Michigan State University
    Panel Members:

    • Arturo Casadevall, MD, PhD, Bloomberg Distinguished Professor, Chair, Department of Molecular Microbiology and Immunology, Johns Hopkins University School of Public Health
    • Sharon Carayiannis, BSMT(ASCP)HP, Vice President, Science and Practice, AABB
    • Jeffrey P. Henderson, MD, PhD, Associate Professor, Medicine and Molecular Microbiology, Washington University School of Medicine
    • Shmuel Shoham, MD, Professor, Johns Hopkins School of Medicine
    • Brenda J. Grossman, MD, MPH, Medical Director Transfusion Medicine Services, Barnes-Jewish Hospital; Professor, Pathology & Immunology and Medicine, Washington University School of Medicine
    • Liise-anne Pirofski, MD, Selma and Dr. Jacques Mitrani Chair in Biomedical Research, Professor and Chief, Division of Infectious Diseases, Albert Einstein College of Medicine and Montefiore Medical Center

    Continuing Education Credit

    Continuing education credit will not be offered for this program.